NDAINHALATION, INJECTIONSOLUTION
Lifecycle
Pre-Launch
Data completeness
1/8 — Limited
XENEISOL (xenon xe-133) by Lantheus Medical Imaging is radiopharmaceutical activity [moa].
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XENEISOL (Xenon Xe-133) is a radiopharmaceutical administered via inhalation or injection for diagnostic imaging purposes. It functions through radiopharmaceutical activity to visualize organ function and perfusion. The product is in pre-launch stage under NDA review by Lantheus Medical Imaging.
Pre-Launch
Pre-launch stage indicates small, focused team preparing for market entry with emphasis on regulatory readiness and initial commercialization infrastructure.
Mechanism of Action
Radiopharmaceutical Activity
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on XENEISOL offers specialized careers in quality and regulatory functions during a critical pre-launch phase. This product presents opportunities in small, high-impact teams focused on bringing a diagnostic radiopharmaceutical to market.
International License Partner Quality Specialist
Quality Assurance
Worked on XENEISOL at Lantheus Medical Imaging? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.